Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 1073-1076

  Crowe Jr , James E ^a   Gilmour, Page S ^b   Murphy, Brian R ^b   Chanock, Robert M ^b   Duan, Lingxun ^b   Pomerantz, Roger J ^b   Pilkington, Glenn R ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ISOLATION; FEMALE; HEP 2 CELL; HUMAN; HUMAN CELL; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS TITRATION;

EID: 0031958658     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517397     Document Type: Article

References (12)

1. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. New York: Lippincott-Raven Press, 1996:1313-51.
2. Pilkington GR, Duan L, Zhu M, Keil W, Pomerantz R. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library. Mol Immunol 1996;33:439-50.
3. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990;8:497-502.
4. Walsh EE, Brandriss MW, Schlesinger JJ. Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 1985;66:409-15.
5. Walsh EE, Schlesinger JJ, Brandriss MW. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol 1984;65:761-7.
6. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966;83:299-313.
7. Barbas CF, Crowe JE Jr, Cababa D, et al. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 1992;89:10164-8.
8. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989;63:2941-50.
9. Arbiza J, Taylor G, Lopez JA, et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1992;73:2225-34.
10. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978;93:771-91.
11. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395-404.
12. Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF III, Burton DR. Recombinant human RSV monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of respiratory syncytial virus - infected mice. Proc Natl Acad Sci USA 1994;91:1386-90.